1. Pink Sheet

US FDA Tech Modernization Plan’s Costs Uncertain

 
• By Derrick Gingery

Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.

FDA entrance sign 2016
FDA plans to seek out tech companies and their investors for guidance as the Technology Modernization Action Plan moves forward. • Source: File photo

The cost of the US Food and Drug Administration’s ambitious Technology Modernization Action Plan likely will not be known for some time, its chief advocate said.

Principal Deputy Commissioner Amy Abernethy said the agency decided to begin changing its approach to data management using existing budgets first, in the hopes the initial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.